Multinational retrospective study of immune checkpoint inhibitors for advanced penile cancer

Treatment options for penile squamous cell carcinoma (PeCa) are limited. A multinational retrospective study by the Global Society of Rare Genitourinary Tumors found that immune checkpoint inhibitors are active in a subset of patients with locally advanced or metastatic PeCa. The median overall and progression-free survival were 9.8 months and 3.2 months, respectively.